Interleukin-17 and innate immunity in infections and chronic inflammation

Journal of Autoimmunity - Tập 60 - Trang 1-11 - 2015
Natasa Isailovic1, Kenji Daigo2, Alberto Mantovani3, Carlo Selmi4
1Division of Rheumatology and Clinical Immunology, Humanitas Research Hospital, Rozzano, Italy
2Department of Immunology and Inflammation, IRCCS Humanitas Research Hospital, Rozzano, Italy.
3Department of Immunology and Inflammation, IRCCS Humanitas Research Hospital, Rozzano, Italy; Humanitas University, Rozzano, Italy. Electronic address: [email protected].
4Division of Rheumatology and Clinical Immunology, Humanitas Research Hospital, Rozzano, Italy; BIOMETRA Department, University of Milan, Milan, Italy. Electronic address: [email protected].

Tóm tắt

Từ khóa


Tài liệu tham khảo

Medzhitov, 2000, Innate immunity, N. Engl. J. Med., 343, 338, 10.1056/NEJM200008033430506

Feghali, 1997, Cytokines in acute and chronic inflammation, Front. Biosci., 2, d12, 10.2741/A171

Awasthi, 2009, Th17 cells: from precursors to players in inflammation and infection, Int. Immunol., 21, 489, 10.1093/intimm/dxp021

Mosmann, 1989, TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties, Annu Rev. Immunol., 7, 145, 10.1146/annurev.iy.07.040189.001045

Del Prete, 1992, Human Th1 and Th2 lymphocytes: their role in the pathophysiology of atopy, Allergy, 47, 450, 10.1111/j.1398-9995.1992.tb00662.x

Steinke, 2001, Th2 cytokines and asthma. Interleukin-4: its role in the pathogenesis of asthma, and targeting it for asthma treatment with interleukin-4 receptor antagonists, Respir. Res., 2, 66, 10.1186/rr40

Hueber, 2010, Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis, Sci. Transl. Med., 2, 52ra72, 10.1126/scitranslmed.3001107

Schmitt, 2014, Th9 cells, new players in adaptive immunity, Trends Immunol., 35, 61, 10.1016/j.it.2013.10.004

Korn, 2009, IL-17 and Th17 cells, Annu. Rev. Immunol., 27, 485, 10.1146/annurev.immunol.021908.132710

Eyerich, 2009, Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling, J. Clin. Investigation, 119, 3573

O'Shea, 2010, Mechanisms underlying lineage commitment and plasticity of helper CD4+ T cells, Science (New York, NY), 327, 1098, 10.1126/science.1178334

Zhu, 2010, Differentiation of effector CD4 T cell populations (*), Annu. Rev. Immunol., 28, 445, 10.1146/annurev-immunol-030409-101212

Gu, 2013, IL-17 family: cytokines, receptors and signaling, Cytokine, 64, 477, 10.1016/j.cyto.2013.07.022

Rouvier, 1993, CTLA-8, cloned from an activated T cell, bearing AU-rich messenger RNA instability sequences, and homologous to a herpesvirus saimiri gene, J. Immunol., 150, 5445, 10.4049/jimmunol.150.12.5445

Wu, 2013, Induction of pathogenic TH17 cells by inducible salt-sensing kinase SGK1, Nature, 496, 513, 10.1038/nature11984

Kleinewietfeld, 2013, Sodium chloride drives autoimmune disease by the induction of pathogenic TH17 cells, Nature, 496, 518, 10.1038/nature11868

Kolls, 2004, Interleukin-17 family members and inflammation, Immunity, 21, 467, 10.1016/j.immuni.2004.08.018

Iwakura, 2011, Functional specialization of interleukin-17 family members, Immunity, 34, 149, 10.1016/j.immuni.2011.02.012

Miossec, 2012, Targeting IL-17 and TH17 cells in chronic inflammation, Nat. Rev. Drug Discov., 11, 763, 10.1038/nrd3794

Garlanda, 2013, The interleukin-1 family: back to the future, Immunity, 39, 1003, 10.1016/j.immuni.2013.11.010

Hirota, 2012, Regulation and function of innate and adaptive interleukin-17-producing cells, EMBO Rep., 13, 113, 10.1038/embor.2011.248

Lin, 2011, Mast cells and neutrophils release IL-17 through extracellular trap formation in psoriasis, J. Immunol., 187, 490, 10.4049/jimmunol.1100123

Takatori, 2009, Lymphoid tissue inducer-like cells are an innate source of IL-17 and IL-22, J. Exp. Med., 206, 35, 10.1084/jem.20072713

Crellin, 2010, Human NKp44+IL-22+ cells and LTi-like cells constitute a stable RORC+ lineage distinct from conventional natural killer cells, J. Exp. Med., 207, 281, 10.1084/jem.20091509

Michel, 2007, Identification of an IL-17-producing NK1.1(neg) iNKT cell population involved in airway neutrophilia, J. Exp. Med., 204, 995, 10.1084/jem.20061551

Cella, 2009, A human natural killer cell subset provides an innate source of IL-22 for mucosal immunity, Nature, 457, 722, 10.1038/nature07537

Pappu, 2010, The IL-17 family cytokines in immunity and disease, J. Clin. Immunol., 30, 185, 10.1007/s10875-010-9369-6

Geremia, 2011, IL-23-responsive innate lymphoid cells are increased in inflammatory bowel disease, J. Exp. Med., 208, 1127, 10.1084/jem.20101712

Hoshino, 2008, MPO-ANCA induces IL-17 production by activated neutrophils in vitro via classical complement pathway-dependent manner, J. Autoimmun., 31, 79, 10.1016/j.jaut.2008.03.006

Villanova, 2014, Characterization of innate lymphoid cells in human skin and blood demonstrates increase of NKp44+ ILC3 in psoriasis, J. Invest. Dermatol., 134, 984, 10.1038/jid.2013.477

Johansen, 2011, Tumor necrosis factor alpha-mediated induction of interleukin 17C in human keratinocytes is controlled by nuclear factor kappaB, J. Biol. Chem., 286, 25487, 10.1074/jbc.M111.240671

Hueber, 2010, Mast cells express IL-17A in rheumatoid arthritis synovium, J. Immunol., 184, 3336, 10.4049/jimmunol.0903566

Dong, 2014, Targeting Th17 cells in immune diseases, Cell. Res., 24, 901, 10.1038/cr.2014.92

Toussirot, 2012, The IL23/Th17 pathway as a therapeutic target in chronic inflammatory diseases, Inflamm. Allergy Drug Targets, 11, 159, 10.2174/187152812800392805

Zhang, 2003, Induction of experimental autoimmune encephalomyelitis in IL-12 receptor-beta 2-deficient mice: IL-12 responsiveness is not required in the pathogenesis of inflammatory demyelination in the central nervous system, J. Immunol., 170, 2153, 10.4049/jimmunol.170.4.2153

Curtis, 2009, Interleukin-17 in host defence against bacterial, mycobacterial and fungal pathogens, Immunology, 126, 177, 10.1111/j.1365-2567.2008.03017.x

Tsai, 2013, IL-17A and Th17 cells in lung inflammation: an update on the role of Th17 cell differentiation and IL-17R signaling in host defense against infection, Clin. Dev. Immunol., 2013, 267971, 10.1155/2013/267971

Cua, 2010, Innate IL-17-producing cells: the sentinels of the immune system, Nat. Rev. Immunol., 10, 479, 10.1038/nri2800

Kundu-Raychaudhuri, 2014, Kv1.3 in psoriatic disease: PAP-1, a small molecule inhibitor of Kv1.3 is effective in the SCID mouse psoriasis - Xenograft model, J. Autoimmun., 55, 63, 10.1016/j.jaut.2014.07.003

Langrish, 2004, IL-12 and IL-23: master regulators of innate and adaptive immunity, Immunol. Rev., 202, 96, 10.1111/j.0105-2896.2004.00214.x

Deenick, 2007, Autoimmunity: IL-21: a new player in Th17-cell differentiation, Immunol. Cell Biol., 85, 503, 10.1038/sj.icb.7100114

Chen, 2008, Th17 cells: a new fate for differentiating helper T cells, Immunol. Res., 41, 87, 10.1007/s12026-007-8014-9

Sutton, 2009, Interleukin-1 and IL-23 induce innate IL-17 production from gammadelta T cells, amplifying Th17 responses and autoimmunity, Immunity, 31, 331, 10.1016/j.immuni.2009.08.001

Parker, 1990, Evidence for extrathymic changes in the T cell receptor gamma/delta repertoire, J. Exp. Med., 171, 1597, 10.1084/jem.171.5.1597

Cai, 2011, Pivotal role of dermal IL-17-producing gammadelta T cells in skin inflammation, Immunity, 35, 596, 10.1016/j.immuni.2011.08.001

Itohara, 1990, Homing of a gamma delta thymocyte subset with homogeneous T-cell receptors to mucosal epithelia, Nature, 343, 754, 10.1038/343754a0

Goodman, 1989, Intraepithelial lymphocytes. Anatomical site, not T cell receptor form, dictates phenotype and function, J. Exp. Med., 170, 1569, 10.1084/jem.170.5.1569

Gray, 2011, Cutting edge: identification of a motile IL-17-producing gammadelta T cell population in the dermis, J. Immunol., 186, 6091, 10.4049/jimmunol.1100427

Ribot, 2009, CD27 is a thymic determinant of the balance between interferon-gamma- and interleukin 17-producing gammadelta T cell subsets, Nat. Immunol., 10, 427, 10.1038/ni.1717

Haas, 2009, CCR6 and NK1.1 distinguish between IL-17A and IFN-gamma-producing gammadelta effector T cells, Eur. J. Immunol., 39, 3488, 10.1002/eji.200939922

Jensen, 2008, Thymic selection determines gammadelta T cell effector fate: antigen-naive cells make interleukin-17 and antigen-experienced cells make interferon gamma, Immunity, 29, 90, 10.1016/j.immuni.2008.04.022

Korn, 2012, Development and function of interleukin 17-producing gammadelta T cells, Ann. N Y Acad. Sci., 1247, 34, 10.1111/j.1749-6632.2011.06355.x

Caccamo, 2011, Differentiation, phenotype, and function of interleukin-17-producing human Vgamma9Vdelta2 T cells, Blood, 118, 129, 10.1182/blood-2011-01-331298

Kronenberg, 2007, On the road: progress in finding the unique pathway of invariant NKT cell differentiation, Curr. Opin. Immunol., 19, 186, 10.1016/j.coi.2007.02.009

Tatituri, 2013, Recognition of microbial and mammalian phospholipid antigens by NKT cells with diverse TCRs, Proc. Natl. Acad. Sci. U S A., 110, 1827, 10.1073/pnas.1220601110

Maggi, 2010, CD161 is a marker of all human IL-17-producing T-cell subsets and is induced by RORC, Eur. J. Immunol., 40, 2174, 10.1002/eji.200940257

Rossjohn, 2012, Recognition of CD1d-restricted antigens by natural killer T cells, Nat. Rev. Immunol., 12, 845, 10.1038/nri3328

Moreira-Teixeira, 2011, Proinflammatory environment dictates the IL-17-producing capacity of human invariant NKT cells, J. Immunol., 186, 5758, 10.4049/jimmunol.1003043

Kumar, 2014, Innate lymphoid cells: new paradigm in immunology of inflammation, Immunol. Lett., 157, 23, 10.1016/j.imlet.2013.11.003

Waldhauer, 2008, NK cells and cancer immunosurveillance, Oncogene, 27, 5932, 10.1038/onc.2008.267

Poggi, 2014, NK cell autoreactivity and autoimmune diseases, Front. Immunol., 5, 27

Passos, 2010, IL-6 promotes NK cell production of IL-17 during toxoplasmosis, J. Immunol., 184, 1776, 10.4049/jimmunol.0901843

Luci, 2009, Influence of the transcription factor RORgammat on the development of NKp46+ cell populations in gut and skin, Nat. Immunol., 10, 75, 10.1038/ni.1681

Satoh-Takayama, 2009, The natural cytotoxicity receptor NKp46 is dispensable for IL-22-mediated innate intestinal immune defense against Citrobacter rodentium, J. Immunol., 183, 6579, 10.4049/jimmunol.0901935

Sanos, 2010, Isolation of NK cells and NK-like cells from the intestinal lamina propria, Methods Mol. Biol., 612, 505, 10.1007/978-1-60761-362-6_32

Kollnberger, 2002, Cell-surface expression and immune receptor recognition of HLA-B27 homodimers, Arthritis Rheumatism, 46, 2972, 10.1002/art.10605

Scrivo, 2011, Evaluation of degranulation and cytokine production in natural killer cells from spondyloarthritis patients at single-cell level, Cytom. B Clin. Cytom., 80, 22, 10.1002/cyto.b.20549

Kim, 2009, Lymphoid tissue inducer cells: architects of CD4 immune responses in mice and men, Clin. Exp. Immunol., 157, 20, 10.1111/j.1365-2249.2009.03932.x

Cupedo, 2009, Human fetal lymphoid tissue-inducer cells are interleukin 17-producing precursors to RORC+ CD127+ natural killer-like cells, Nat. Immunol., 10, 66, 10.1038/ni.1668

Gladiator, 2013, Cutting edge: IL-17-secreting innate lymphoid cells are essential for host defense against fungal infection, J. Immunol., 190, 521, 10.4049/jimmunol.1202924

Buonocore, 2010, Innate lymphoid cells drive interleukin-23-dependent innate intestinal pathology, Nature, 464, 1371, 10.1038/nature08949

Sawa, 2011, RORgammat+ innate lymphoid cells regulate intestinal homeostasis by integrating negative signals from the symbiotic microbiota, Nat. Immunol., 12, 320, 10.1038/ni.2002

Sadik, 2011, Neutrophils cascading their way to inflammation, Trends Immunol., 32, 452, 10.1016/j.it.2011.06.008

Mantovani, 2011, Neutrophils in the activation and regulation of innate and adaptive immunity, Nat. Rev., 11, 519

Ley, 2007, Getting to the site of inflammation: the leukocyte adhesion cascade updated, Nat. Rev., 7, 678

Ramirez-Carrozzi, 2011, IL-17C regulates the innate immune function of epithelial cells in an autocrine manner, Nat. Immunol., 12, 1159, 10.1038/ni.2156

Li, 2010, IL-17 produced by neutrophils regulates IFN-gamma-mediated neutrophil migration in mouse kidney ischemia-reperfusion injury, J. Clin. Invest., 120, 331, 10.1172/JCI38702

Metcalfe, 1997, Mast cells, Physiol. Rev., 77, 1033, 10.1152/physrev.1997.77.4.1033

Stone, 2010, IgE, mast cells, basophils, and eosinophils, J. Allergy Clin. Immunol., 125, S73, 10.1016/j.jaci.2009.11.017

Sakellariou, 2014, Association of Smoking with acute phase Reactants and molecules involved in bone formation in patients with ankylosing spondylitis, Arthritis Rheumatol., 66, S1130

Zizzo, 2013, IL-17 stimulates differentiation of human anti-inflammatory macrophages and phagocytosis of apoptotic neutrophils in response to IL-10 and glucocorticoids, J. Immunol., 190, 5237, 10.4049/jimmunol.1203017

Erbel, 2014, IL-17A influences essential functions of the monocyte/macrophage lineage and is involved in advanced murine and human atherosclerosis, J. Immunol., 193, 4344, 10.4049/jimmunol.1400181

Sutherland, 2014, Chitinase-like proteins promote IL-17-mediated neutrophilia in a tradeoff between nematode killing and host damage, Nat. Immunol., 15, 1116, 10.1038/ni.3023

Murray, 2014, Macrophage activation and polarization: nomenclature and experimental guidelines, Immunity, 41, 14, 10.1016/j.immuni.2014.06.008

Wang, 2014, IL-17 induces inflammation-associated gene products in blood monocytes, and treatment with ixekizumab reduces their expression in psoriasis patient blood, J. Invest. Dermatol., 134, 2990, 10.1038/jid.2014.268

Ishigame, 2009, Differential roles of interleukin-17A and -17F in host defense against mucoepithelial bacterial infection and allergic responses, Immunity, 30, 108, 10.1016/j.immuni.2008.11.009

Chen, 2003, Stimulation of airway mucin gene expression by interleukin (IL)-17 through IL-6 paracrine/autocrine loop, J. Biol. Chem., 278, 17036, 10.1074/jbc.M210429200

Liang, 2006, Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides, J. Exp. Med., 203, 2271, 10.1084/jem.20061308

Jovanovic, 1998, IL-17 stimulates the production and expression of proinflammatory cytokines, IL-beta and TNF-alpha, by human macrophages, J. Immunol., 160, 3513, 10.4049/jimmunol.160.7.3513

Ouyang, 2008, The biological functions of T helper 17 cell effector cytokines in inflammation, Immunity, 28, 454, 10.1016/j.immuni.2008.03.004

Pappu, 2012, Regulation of epithelial immunity by IL-17 family cytokines, Trends Immunol., 33, 343, 10.1016/j.it.2012.02.008

Kleinschek, 2007, IL-25 regulates Th17 function in autoimmune inflammation, J. Exp. Med., 204, 161, 10.1084/jem.20061738

Reynolds, 2010, IL-17 family member cytokines: regulation and function in innate immunity, Cytokine Growth Factor Rev., 21, 413, 10.1016/j.cytogfr.2010.10.002

Dungan, 2011, Caspase-1-processed IL-1 family cytokines play a vital role in driving innate IL-17, Cytokine, 56, 126, 10.1016/j.cyto.2011.07.007

Kinugasa, 2000, Claudins regulate the intestinal barrier in response to immune mediators, Gastroenterology, 118, 1001, 10.1016/S0016-5085(00)70351-9

Moran, 2009, Human rheumatoid arthritis tissue production of IL-17A drives matrix and cartilage degradation: synergy with tumour necrosis factor-alpha, Oncostatin M and response to biologic therapies, Arthritis Res. Ther., 11, R113, 10.1186/ar2772

Svendsen, 2013, The impact of genes on the occurrence of autoantibodies in rheumatoid arthritis. A study on disease discordant twin pairs, J. Autoimmun., 41, 120, 10.1016/j.jaut.2012.12.001

Kourilovitch, 2014, Diagnosis and classification of rheumatoid arthritis, J. Autoimmun., 48–49, 26, 10.1016/j.jaut.2014.01.027

Chabaud, 2000, Contribution of interleukin 17 to synovium matrix destruction in rheumatoid arthritis, Cytokine, 12, 1092, 10.1006/cyto.2000.0681

Andoh, 2007, Interaction between interleukin-17-producing CD4+ T cells and colonic subepithelial myofibroblasts: what are they doing in mucosal inflammation?, J. Gastroenterology, 42, 29, 10.1007/s00535-006-1926-7

Huppert, 2010, Cellular mechanisms of IL-17-induced blood-brain barrier disruption, FASEB J. Official Publ. Fed. Am. Soc. Exp. Biol., 24, 1023

Gaffen, 2014, The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing, Nat. Rev. Immunol., 14, 585, 10.1038/nri3707

Liubchenko, 2013, Rheumatoid arthritis is associated with signaling alterations in naturally occurring autoreactive B-lymphocytes, J. Autoimmun., 40, 111, 10.1016/j.jaut.2012.09.001

Diani, 2015, T cell responses in psoriasis and psoriatic arthritis, Autoimmun. Rev., 14, 286, 10.1016/j.autrev.2014.11.012

Zhang, 2013, Whole-genome DNA methylation in skin lesions from patients with psoriasis vulgaris, J. Autoimmun., 41, 17, 10.1016/j.jaut.2013.01.001

Modena, 2013, Cost-effectiveness of biologic treatment for rheumatoid arthritis in clinical practice: an achievable target?, Autoimmun. Rev., 12, 835, 10.1016/j.autrev.2012.11.009

Roark, 2007, Exacerbation of collagen-induced arthritis by oligoclonal, IL-17-producing gamma delta T cells, J. Immunol., 179, 5576, 10.4049/jimmunol.179.8.5576

Roark, 2013, A canonical Vgamma4Vdelta4+ gammadelta T cell population with distinct stimulation requirements which promotes the Th17 response, Immunol. Res., 55, 217, 10.1007/s12026-012-8364-9

Ito, 2009, Gamma/delta T cells are the predominant source of interleukin-17 in affected joints in collagen-induced arthritis, but not in rheumatoid arthritis, Arthritis Rheumatism, 60, 2294, 10.1002/art.24687

O'Brien, 2001, T cell receptor and function cosegregate in gamma-delta T cell subsets, Chem. Immunol., 79, 1, 10.1159/000058829

Pollinger, 2011, Th17 cells, not IL-17+ gammadelta T cells, drive arthritic bone destruction in mice and humans, J. Immunol., 186, 2602, 10.4049/jimmunol.1003370

Keijsers, 2014, Cellular sources of IL-17 in psoriasis: a paradigm shift?, Exp. Dermatol., 23, 799, 10.1111/exd.12487

Kirkham, 2014, Interleukin-17A: a unique pathway in immune-mediated diseases: psoriasis, psoriatic arthritis and rheumatoid arthritis, Immunology, 141, 133, 10.1111/imm.12142

Conrad, 2006, Animal models of psoriasis and psoriatic arthritis: an update, Curr. Rheumatol. Reports, 8, 342, 10.1007/s11926-006-0063-x

Noordenbos, 2012, Interleukin-17-positive mast cells contribute to synovial inflammation in spondylarthritis, Arthritis Rheumatism, 64, 99, 10.1002/art.33396

Raychaudhuri, 2012, IL-17 receptor and its functional significance in psoriatic arthritis, Mol. Cell. Biochem., 359, 419, 10.1007/s11010-011-1036-6

de Boer, 2010, Differential expression of interleukin-17 family cytokines in intact and complicated human atherosclerotic plaques, J. Pathol., 220, 499, 10.1002/path.2667

Pantelyushin S, Haak S, Ingold B, Kulig P, Heppner FL, Navarini AA et al. Rorgammat+ innate lymphocytes and gammadelta T cells initiate psoriasiform plaque formation in mice. J. Clin. Invest.;122:2252–2256..

Batliwalla, 2005, Microarray analyses of peripheral blood cells identifies unique gene expression signature in psoriatic arthritis, Mol. Med., 11, 21, 10.2119/2006-00003.Gulko

Bozza, 2008, Lack of Toll IL-1R8 exacerbates Th17 cell responses in fungal infection, J. Immunol., 180, 4022, 10.4049/jimmunol.180.6.4022

Gulen, 2010, The receptor SIGIRR suppresses Th17 cell proliferation via inhibition of the interleukin-1 receptor pathway and mTOR kinase activation, Immunity, 32, 54, 10.1016/j.immuni.2009.12.003

Russell, 2013, Toll IL-1R8/single Ig IL-1-related receptor regulates psoriasiform inflammation through direct inhibition of innate IL-17A expression by gammadelta T cells, J. Immunol., 191, 3337, 10.4049/jimmunol.1300828

Glitzner E, Korosec A, Brunner PM, Drobits B, Amberg N, Schonthaler HB et al. Specific roles for dendritic cell subsets during initiation and progression of psoriasis. EMBO Mol. Med.;6:1312–1327..

Boltjes A, van Wijk F. Human dendritic cell functional specialization in steady-state and inflammation. Front. Immunol.;5:131..

Cooper, 2009, IL-17 and anti-bacterial immunity: protection versus tissue damage, Eur. J. Immunol., 39, 649, 10.1002/eji.200839090

Leon, 2013, IL-17-producing B cells combat parasites, Nat. Immunol., 14, 419, 10.1038/ni.2593

Lockhart, 2006, IL-17 production is dominated by gammadelta T cells rather than CD4 T cells during Mycobacterium tuberculosis infection, J. Immunol., 177, 4662, 10.4049/jimmunol.177.7.4662

Okamoto Yoshida, 2010, Essential role of IL-17A in the formation of a mycobacterial infection-induced granuloma in the lung, J. Immunol., 184, 4414, 10.4049/jimmunol.0903332

Umemura, 2007, IL-17-mediated regulation of innate and acquired immune response against pulmonary Mycobacterium bovis bacille Calmette-Guerin infection, J. Immunol., 178, 3786, 10.4049/jimmunol.178.6.3786

Tam, 2012, IL-17 and gammadelta T-lymphocytes play a critical role in innate immunity against Nocardia asteroides GUH-2, Microbes Infect./Institut. Pasteur., 14, 1133, 10.1016/j.micinf.2012.05.008

Liu, 2013, The responses of gammadelta T-cells against acute Pseudomonas aeruginosa pulmonary infection in mice via interleukin-17, Pathogens Dis., 68, 44, 10.1111/2049-632X.12043

Shibata, 2007, Resident Vdelta1+ gammadelta T cells control early infiltration of neutrophils after Escherichia coli infection via IL-17 production, J. Immunol., 178, 4466, 10.4049/jimmunol.178.7.4466

Cho, 2010, IL-17 is essential for host defense against cutaneous Staphylococcus aureus infection in mice, J. Clin. Invest., 120, 1762, 10.1172/JCI40891

Hamada, 2008, IL-17A produced by gammadelta T cells plays a critical role in innate immunity against listeria monocytogenes infection in the liver, J. Immunol., 181, 3456, 10.4049/jimmunol.181.5.3456

Hamada, 2008, Importance of murine Vdelta1gammadelta T cells expressing interferon-gamma and interleukin-17A in innate protection against Listeria monocytogenes infection, Immunology, 125, 170, 10.1111/j.1365-2567.2008.02841.x

Zhang, 2013, IL-17 plays a central role in initiating experimental Candida albicans infection in mouse corneas, Eur. J. Immunol., 43, 2671, 10.1002/eji.201242891

Jie, 2014, Intrahepatic innate lymphoid cells secrete IL-17A and IL-17F that are crucial for T cell priming in viral infection, J. Immunol., 192, 3289, 10.4049/jimmunol.1303281

Peng, 2008, Interleukin 17-producing gamma delta T cells increased in patients with active pulmonary tuberculosis, Cell. Mol. Immunol., 5, 203, 10.1038/cmi.2008.25

Asano T, Ichiki K, Koizumi S, Kaizu K, Hatori T, Fujino O et al. IL-17 is elevated in cerebrospinal fluids in bacterial meningitis in children. Cytokine;51:101–106..

Raychaudhuri, 2013, Role of IL-17 in psoriasis and psoriatic arthritis, Clin. Rev. Allergy Immunol., 44, 183, 10.1007/s12016-012-8307-1

Benham, 2013, Th17 and Th22 cells in psoriatic arthritis and psoriasis, Arthritis Res. Ther., 15, R136, 10.1186/ar4317

Chiricozzi, 2013, IL-17 targeted therapies for psoriasis, Expert Opin. Invest. Drugs, 22, 993, 10.1517/13543784.2013.806483

Leonardi, 2012, Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis, N. Engl. J. Med., 366, 1190, 10.1056/NEJMoa1109997

Papp, 2013, Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study, Br. J. Dermatol., 168, 412, 10.1111/bjd.12110

Puel, 2011, Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity, Science, 332, 65, 10.1126/science.1200439

Milner, 2008, Impaired T(H)17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome, Nature, 452, 773, 10.1038/nature06764

Papp, 2012, Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis, N. Engl. J. Med., 366, 1181, 10.1056/NEJMoa1109017

Genovese, 2013, Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study, Ann. Rheumatic Dis., 72, 863, 10.1136/annrheumdis-2012-201601

Genovese, 2014, One-year efficacy and safety results of secukinumab in patients with rheumatoid arthritis: phase II, dose-finding, double-blind, randomized, placebo-controlled study, J. Rheumatol., 41, 414, 10.3899/jrheum.130637

Genovese, 2010, LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I randomized, double-blind, placebo-controlled, proof-of-concept study, Arthritis Rheumat., 62, 929, 10.1002/art.27334

Genovese, 2014, A phase II randomized study of subcutaneous ixekizumab, an anti-interleukin-17 monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic agents or had an inadequate response to tumor necrosis factor inhibitors, Arthritis Rheumatol., 66, 1693, 10.1002/art.38617

Martin, 2013, A phase Ib multiple ascending dose study evaluating safety, pharmacokinetics, and early clinical response of brodalumab, a human anti-IL-17R antibody, in methotrexate-resistant rheumatoid arthritis, Arthritis Res. Ther., 15, R164, 10.1186/ar4347

Langley, 2014, Secukinumab in plaque psoriasis–results of two phase 3 trials, N. Engl. J. Med., 371, 326, 10.1056/NEJMoa1314258

McInnes, 2014, Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial, Ann. Rheumat. Dis., 73, 349, 10.1136/annrheumdis-2012-202646

Mease, 2014, Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis, Drugs, 74, 423, 10.1007/s40265-014-0191-y

Mease, 2014, Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis, N. Engl. J. Med., 370, 2295, 10.1056/NEJMoa1315231

Bugatti, 2011, Synovial tissue heterogeneity and peripheral blood biomarkers, Curr. Rheumatol. Reports, 13, 440, 10.1007/s11926-011-0201-y

Talamonti, 2013, Pharmacogenetics of psoriasis: HLA-Cw6 but not LCE3B/3C deletion nor TNFAIP3 polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinumab, Br. J. Dermatol., 169, 458, 10.1111/bjd.12331

Rodriguez-Carrio, 2015, Type I IFNs as biomarkers in rheumatoid arthritis: towards disease profiling and personalized medicine, Clin. Sci., 128, 449, 10.1042/CS20140554

de Punder, 2015, A Simplified Baseline Prediction model for joint damage progression in rheumatoid arthritis: a Step toward personalized medicine, J. Rheumatol., 42, 391, 10.3899/jrheum.140327

Coimbra, 2014, Brodalumab: an evidence-based review of its potential in the treatment of moderate-to-severe psoriasis, Core Evid., 9, 89, 10.2147/CE.S33940

Gordon, 2014, A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis, J. Am. Acad. Dermatol., 71, 1176, 10.1016/j.jaad.2014.07.048

Sanford, 2015, Secukinumab: first global approval, Drugs, 75, 329, 10.1007/s40265-015-0359-0

Gisondi, 2014, Efficacy and safety of secukinumab in chronic plaque psoriasis and psoriatic arthritis therapy, Dermatol. Ther., 4, 1, 10.1007/s13555-014-0042-5

Ritchlin, 2014, Ann. Rheumatic Dis., 73, 990, 10.1136/annrheumdis-2013-204655

Khanna, 2013, Ustekinumab for the treatment of Crohn's disease, Immunotherapy, 5, 803, 10.2217/imt.13.81

Yiu, 2015, Efficacy and safety of emerging immunotherapies in psoriasis, Immunotherapy, 7, 119, 10.2217/imt.14.101

Krueger, 2015, Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial, J. Allergy Clin. Immunol., 10.1016/j.jaci.2015.01.018